B+
Bull case
25%
Probability
Target price
$2.72
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
BDTX
Black Diamond TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Silevertinib has encouraging preliminary activity in non-classical EGFR-mutant NSCLC, including CNS responses, no reported de novo brain metastases, and a potential Q4 FDA pivotal-path update [#SEC-8K-2026-08-05]. The extended runway supports continued development without immediate financing dependence.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash declined from $128.7 million at year-end 2025 to $110.5 million at June 30, 2026; additional financing could eventually be required despite the stated runway [#SEC-8K-2026-08-05].
Momentum
77
Value
44
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.22 · Bull $2.72 · Bear $1.41Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum77 · Δ7d -
Value44 · Δ7d -0.0
Sentiment73 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Cash declined from $128.7 million at year-end 2025 to $110.5 million at June 30, 2026; additional financing could eventually be required despite the stated runway [#SEC-8K-2026-08-05].
- • Low coverage and loose peers limit confidence in valuation and market-expectation assessment.
- • The clinical evidence remains preliminary and based on a relatively small Phase 2 population.
Catalyst clock
2026-12-31
Q4 2026 NSCLC update and FDA pivotal-path feedback
Lead driver: Sentiment · See AI snapshot
Momentum
77
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-16.0
Sentiment
73
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 77.0 / Value 44.3 / Sentiment 73.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.22
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.41
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$117.78M
Beta
3.37
Shares Out
57.45M
P/E (TTM)
7.1
P/S (TTM)
2.09
P/FCF (TTM)
6.86
Rev YoY
-100.0%
EPS YoY
-7.1%
Gross Margin
+99.5%
Op Margin
+16.9%
Net Debt
-$109.87M
Current Ratio
7.28
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data